Academic literature on the topic 'Obesity; Neoplasm; Breast Cancer'
Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles
Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Obesity; Neoplasm; Breast Cancer.'
Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.
You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.
Journal articles on the topic "Obesity; Neoplasm; Breast Cancer"
1
Piccoli, Giovana Fagundes, Leonardo A. Mesquita, Cinara Stein, et al. "Do GLP-1 Receptor Agonists Increase the Risk of Breast Cancer? A Systematic Review and Meta-Analysis." Journal of the Endocrine Society 5, Supplement_1 (2021): A352—A353. http://dx.doi.org/10.1210/jendso/bvab048.718.
Full textAbstract:
Abstract Background: Risk of cancer is a major concern in the development of drugs for the treatment of obesity and diabetes. In randomized controlled trials (RCTs) of the liraglutide development program, a glucagon-like peptide-1 receptor agonist (GLP-1RA), subjects treated with the active drug had a higher absolute number of breast cancer events. Aim: To assess whether patients treated with GLP-1RAs had a higher risk of breast neoplasms. Methods: We searched MEDLINE, Embase, Web of Science, and CENTRAL from inception to February 8, 2020. Three pairs of reviewers examined and retrieved abstractsand full-text articles for RCTs of GLP-1RAs versus non-GLP-1RA controls(active or placebo) in adults with overweight, obesity, prediabetes, or diabetes,with a minimum follow-up period of 24 weeks and which reported at least oneevent of breast cancer or benign breast neoplasm. Divergences were dealt withby consensus. Researchers extracted study-level data and assessed within-study risk of bias with the RoB 2.0 tool and quality of evidence with GRADE. This study follows PRISMA reporting guidelines. Results: We included 52 trials, of which 50 reported breast cancer events and 11 reported benign breast neoplasms. Overall methodological quality was high. Among 48267 subjects treated with GLP-1RAs, 130 developed breast cancer compared to 107 of 40755 controls (relative risk [RR], 0.98; 95% confidence interval [CI], 0.76 to 1.26). Subset analyses according to follow-up, participant/investigator blinding, and type of GLP-1RA did not reveal any differences. The risk of benign breast neoplasms also did not differ between groups (RR, 0.99; 95% CI, 0.48 to 2.01). Trial sequential analysis provided evidence that the sample size was sufficient to avoid missing alternative results. Conclusion: Treatment with GLP-1RAs for obesity and diabetes does not increase the risk of breast neoplasms. Register: This systematic review was preregistered in PROSPERO (CRD42019132704).
2
Harborg, Sixten, Deirdre Cronin-Fenton, Maj-Britt Raaby Jensen, Thomas P. Ahern, Marianne Ewertz, and Signe Borgquist. "Obesity and Risk of Recurrence in Patients With Breast Cancer Treated With Aromatase Inhibitors." JAMA Network Open 6, no. 10 (2023): e2337780. http://dx.doi.org/10.1001/jamanetworkopen.2023.37780.
Full textAbstract:
ImportanceClinical studies confirm that obesity is a risk factor for recurrence in postmenopausal women with hormone receptor–positive (HR+) breast cancer. Evidence suggests that women with obesity do not obtain similar protection from aromatase inhibitors as women with healthy weight.ObjectiveTo examine the associations of body mass index (BMI) with recurrence.Design, Setting, and ParticipantsThe cohort study was conducted using data from the Danish Breast Cancer Group and enrolled postmenopausal women diagnosed with stage I to III HR+ breast cancer from 1998 through 2016. Data analysis was conducted from November 2022 to April 2023.ExposuresBMI was classified as (1) healthy weight (18.5-24.9), (2) overweight (25.0-29.9), (3) obesity (30.0-34.9), and (4) severe obesity (≥35.0) using the World Health Organization guidelines. Healthy weight was considered the reference group in statistical analyses.Main Outcomes and MeasuresFollow-up began 6 months after breast cancer surgery and continued until the first event of recurrence, contralateral breast cancer, new primary malignant neoplasm, death, emigration, end of clinical follow-up at 10 years, or September 25, 2018. Cox regression was used to estimate crude and adjusted hazard ratios with 95% CIs, adjusting for patient, tumor, and treatment characteristics.ResultsA total of 13 230 patients (median [IQR] age at diagnosis, 64.4 [58.6-70.2] years) with information on BMI were enrolled. There were 1587 recurrences with a median (IQR) potential estimated follow-up of 6.2 (3.6-8.5) years. Multivariable analyses revealed increased recurrence hazards associated with obesity (adjusted hazard ratio, 1.18 [95% CI, 1.01-1.37]) and severe obesity (adjusted hazard ratio, 1.32 [95% CI, 1.08-1.62]) vs patients with healthy weight. Patients with overweight had a greater risk, but the results were not statistically significant (adjusted hazard ratio, 1.10 [95% CI, 0.97-1.24]).Conclusions and RelevanceIn this study, obesity was associated with an increased risk of breast cancer recurrence among postmenopausal patients with HR+ early-stage breast cancer treated with aromatase inhibitors. Physicians should be aware of the significance of obesity on breast cancer outcomes to secure optimal treatment benefit in all patients.
3
González Chico, María Gabriela, Ledis Fernanda Polanco Montaño, Xaviera Elizabeth Medina Godoy, and Cristina Magdalena Abifadel Cazar. "Systematic Review on: Breast Cancer and its Relationship with Prolonged Use of Combined Oral Contraceptives." Más Vita 6, no. 2 (2024): 18–28. http://dx.doi.org/10.47606/acven/mv0234.
Full textAbstract:
Introduction: Breast cancer is a neoplasm in breast tissues, diagnosed in 1 in 8 women, making it one of the most common cancers in the female population. Objective: To analyze the relationship between the constant use of oral contraceptives and the risk of developing breast cancer. Methodology: A systematic review was conducted using the Prisma method, utilizing PubMed and SCOPUS, selecting 14 relevant articles. Results: The reviewed studies showed variable results. Some studies with small samples found some association, while studies with larger populations did not confirm this relationship. Prolonged use of oral contraceptives was associated with a higher risk in young women. Factors such as advanced age at first childbirth and smoking also increased the risk. Most studies highlighted prolonged use (5 to 10 years) as a potential risk, along with modifiable factors like smoking and obesity. Discussion: Although some studies suggest a possible association between oral contraceptives and breast cancer, the results are inconclusive. Additional factors complicate interpretation. Conclusion: More research with large populations is needed to better understand the relationship between oral contraceptives and breast cancer.
4
Nahmias Blank, Daniela, Esther Hermano, Amir Sonnenblick, et al. "Macrophages Upregulate Estrogen Receptor Expression in the Model of Obesity-Associated Breast Carcinoma." Cells 11, no. 18 (2022): 2844. http://dx.doi.org/10.3390/cells11182844.
Full textAbstract:
Breast cancer (BC) and obesity are two heterogeneous conditions with a tremendous impact on health. BC is the most commonly diagnosed neoplasm and the leading cause of cancer-related mortality among women, and the prevalence of obesity in women worldwide reaches pandemic proportions. Obesity is a significant risk factor for both incidence and worse prognosis in estrogen receptor positive (ER+) BC. Yet, the mechanisms underlying the association between excess adiposity and increased risk/therapy resistance/poorer outcome of ER+, but not ER−negative (ER−), BC are not fully understood. Tumor-promoting action of obesity, predominantly in ER + BC patients, is often attributed to the augmented production of estrogen in ‘obese’ adipose tissue. However, in addition to the estrogen production, expression levels of ER represent a key determinant in hormone-driven breast tumorigenesis and therapy response. Here, utilizing in vitro and in vivo models of BC, we show that macrophages, whose adverse activation by obesogenic substances is fueled by heparanase (extracellular matrix-degrading enzyme), are capable of upregulating ER expression in tumor cells, in the setting of obesity-associated BC. These findings underscore a previously unknown mechanism through which interplay between cellular/extracellular elements of obesity-associated BC microenvironment influences estrogen sensitivity—a critical component in hormone-related cancer progression and resistance to therapy.
5
Shalini, Das, Jahan Nushrat, and Mal Chittabrata. "In-silico Identification of lncRNA Functionality in Cancers Related to Obesity." International Journal of BioSciences and Technology (IJBST) ISSN: 0974-3987 13, no. 3 (2020): 34–41. https://doi.org/10.5281/zenodo.4275605.
Full textAbstract:
<strong><em>In-silico</em> Identification of lncRNA Functionality in Cancers Related to Obesity</strong> Shalini Das, Nushrat Jahan and Chittabrata Mal Amity Institute of Biotechnology, Amity University Kolkata, Rajarhat, Newtown, Action Area III, North 24 PGS, 700135, INDIA shweata7@gmail.com, nushratjahan8456@gmail.com, cmal@kol.amity.edu <strong>ABSTRACT:</strong> Investigating the gene expression networks that regulate cancer initiation and development is crucial but remains mostly incomplete. With the innovations in RNA-sequencing technologies and computational biology, long noncoding RNAs (lncRNAs) are being known and characterized at a speedy pace. Recent findings reveal that lncRNAs are involved in serial steps of cancer development. These lncRNAs act with DNA, RNA, protein molecules and/or their combos, acting as a vital regulator in chromatin organization, as well as transcriptional and post-transcriptional regulation. Their aberrant expression confers the neoplastic cell capacities for neoplasm initiation, growth, and metastasis. Here we emphasize their aberrant expression and performance in cancers. We found that Chromosome 11 consists of the highest number of lncRNA specific to different 14 cancers related to obesity. Among these cancers, breast cancer has the highest number of lncRNA associated with it. The interacting partners of the lncRNAs were analysed and domain specific interactions were studied. The results showed that the lncRNAs H19 and MALAT1 can act as potential biomarkers for different cancers. Keywords: lncRNA, gene expression, cancer, obesity, tumor suppression URL: https://www.ijbst.org/papers-published/ijbst-2020-volume-13-issue-3
6
Reytor-González, Claudia, Ana Karina Zambrano, Evelyn Frias-Toral, Martín Campuzano-Donoso, and Daniel Simancas-Racines. "Mediterranean diet and breast cancer: A narrative review." Medwave 25, no. 02 (2025): e3027-e3027. https://doi.org/10.5867/medwave.2025.02.3027.
Full textAbstract:
Breast cancer is the second most common neoplasm and the deadliest among women worldwide. Its incidence varies according to human development and is associated with several risk factors, including age, genetic factors, obesity, and dietary habits. Recent research has revealed a significant influence of dietary habits on the onset and progression of this disease, which is why this review aims to comprehensively analyze the available literature to understand better the role played by the mediterranean diet in the development and management of breast cancer. The mediterranean diet has anti-inflammatory and antioxidant effects, may influence gene regulation, and produce hormonal and intestinal microbiota changes, resulting in improved quality of life for breast cancer patients by alleviating symptoms such as pain, inflammation, and reducing the risk and mortality from this disease. Evidence suggests that greater adherence to the mediterranean diet reduces the risk of breast cancer, as well as an improvement in patients' quality of life and mortality. These findings underscore its potential relevance in the context of dietary patterns associated with breast cancer prevention and management, which could inform considerations for public health policies. Further research is needed to confirm these observations and to understand the underlying mechanisms better.
7
Ayara, Almeida Souza Cabral, Quaresma Trindade Joseelma, Quaresma Trindade Josinaide, et al. "PREVALÊNCIA DA OBESIDADE NOS ASPECTOS DE OCORRÊNCIA DO CÂNCER DE MAMA." Revistaft 27, no. 121 (2023): 48. https://doi.org/10.5281/zenodo.7843848.
Full textAbstract:
<strong>INTRODUÇÃO:</strong> O câncer de mama se caracteriza como uma disfunção celular, em que há uma proliferação exacerbada de determinadas células do nosso corpo, em que sua multiplicação rápida e desordenada caracteriza como uma neoplasia maligna resultando em um tumor, seus fatores para esse comportamento podem estar relacionados à ambientais ou genéticos. Estudos têm mostrado que a obesidade tem ação direta no desenvolvimento de câncer de mama e seu mecanismo de inflamação corporal tem contribuído para que a incidência dessa neoplasia esteja cada vez mais presente na sociedade. <strong>OBJETIVO</strong>: Analisar e discorrer sobre a prevalência da obesidade nos aspectos de ocorrência do câncer de mama. <strong>METODOLOGIA</strong>: Trata-se de uma revisão integrativa da literatura, com abordagem qualitativa e descritiva, realizada de janeiro à março de 2023, com a questão norteadora: “Qual a prevalência da obesidade nos aspectos de ocorrência do câncer de mama? ”As bases de dados utilizadas foram Scielo, Lilacs e PubMed, utilizou-se os descritores Decs sob aplicação do operador booleano AND. “Obesidade”, “Câncer de mama”, “Neoplasias”, “Fatores de Prevalência” Artigos na janela temporal de 2019 a 2023. <strong>RESULTADOS:</strong> Mediante análise dos estudos, constatou-se que a obesidade influencia substancialmente na ocorrência do câncer de mama, com prevalência em mulheres, no entanto, o aumento do sobrepeso em homens têm sido preocupação para o crescimento de desenvolvimento da neoplasia, em uma classe considerada de ocorrência rara. Além disso, as taxas de obesos no Brasil têm crescido com expectativas alarmantes para os próximos anos, atribuindo ainda a relação direta para o crescimento da patologia na mesma proporção, sendo indiscutível ser um problema de saúde pública. <strong>CONSIDERAÇÕES FINAIS:</strong> Em síntese, nota-se que os dados obtidos demonstram ação direta e preocupante que a obesidade desempenha nos aspectos de ocorrência do câncer de mama, além da larga incidência e crescimento da associação obesidade e neoplasia mamária. Para tanto, acendendo o alerta para mudanças de hábitos e necessidade de políticas públicas na saúde.
8
Macciò, Antonio, and Clelia Madeddu. "Obesity, Inflammation, and Postmenopausal Breast Cancer: Therapeutic Implications." Scientific World JOURNAL 11 (2011): 2020–36. http://dx.doi.org/10.1100/2011/806787.
Full textAbstract:
Breast cancer is the female malignant neoplasia with the highest incidence in the industrialized world. Although early diagnosis has contributed to therapeutic success, breast cancer remains a major health issue. In the last few year the hormone therapy for estrogen-dependent breast cancer has evolved achieving significant clinical results; at the same time, it has enabled us to better define the role of estrogens in the etiopathogenesis of this tumour. Weight increase and obesity have been identified as the most important risk and prognostic factors for breast cancer in postmenopausal women. Several hypotheses have been proposed to explain the association of obesity with postmenopausal breast cancer. Specific obesity-associated factors, including leptin, insulin and inflammatory mediators, seem to influence breast cancer growth and prognosis independently of estrogens and at least in part by interacting with estrogen signalling at a cellular level. Therefore, a careful assessment of the nutritional status and body composition is paramount for a proper therapeutic approach for postmenopausal breast carcinoma. The use of antidiabetic and anti-inflammatory drugs associated with conventional hormone therapies and dietary/physical interventions could offer a new therapeutic approach for breast carcinoma that develops in the context of adiposity.
9
Shveid Gerson, Daniela, Alejandro Zentella - Dehesa, Raquel Gerson Cwilich, et al. "Creation of a primary breast cancer culture repository from patients with a BMI >30 kg/m2: A Mexican endeavor." Journal of Clinical Oncology 39, no. 15_suppl (2021): e12574-e12574. http://dx.doi.org/10.1200/jco.2021.39.15_suppl.e12574.
Full textAbstract:
e12574 Background: Currently there are no primary cultures or cell lines derived from patients with breast cancer and obesity. It has been postulated that breast cancer in obese women behaves differently as it does in non-obese women, as is composed of distinct biological features, as was generated in a different metabolic environment, as well as pertains to a different prognosis and different response to chemotherapy, lower rates of overall survival and a greater probability of recurrence. By creating a primary breast cancer culture bank of breast cancer tumors from women with obesity (BMI > 30kg/m2), we will establish a cell line exclusive to obese women in Mexico, where targeted therapy may be tested and treatment may be individualized depending on the characteristics of the patient. Methods: This study recruited 32 women with breast cancer and a BMI > 30 kg/m2, matched by 6 controls with are non-obese women with breast cancer. Elegibility criteria was determined by women with breast cancer confirmed by pathology, who had not been subjected to prior treatment regarding the neoplasm. The breast cancer removing surgeries and the patients were selected from the ABC Medical Center in Mexico City and all procedures were approved by the research and ethics committee of the hospital in question. Results: Through extensive communication a cooperative protocol was established between the departments of surgery, oncology, pathology and nursing to coordinate efforts and be able to take a 2 – 5 mm sample of the breast tumor removed from the patient. To be able to distinguish cancer cells from non-cancer cells (epithelial cells, fibroblasts, adipocytes) the Hayflick limit was be utilized. Once a primary breast cancer culture was established, 12 million cells will be injected into the subscapular area of athymic, nu-nu mice to be able to monitor tumoral growth in vivo and conduct a subsequent cellular analysis, determining it still pertains to the same characteristics of the tumor from which it was obtained. Conclusions: A primary breast cancer culture repository from patients with a BMI > 30 kg/m2 was established. This is the first primary breast cancer culture for both Mexican and obese women with breast cancer, the first in vitro method of analysis of specific characteristics typical of the Mexican population. Translational research may now be conducted on these new tumoral cultures to create individualized therapy for women with the distinct, aforementioned characteristics.
10
Biello, Federica, Francesca Platini, Francesca D’Avanzo, et al. "Insulin/IGF Axis in Breast Cancer: Clinical Evidence and Translational Insights." Biomolecules 11, no. 1 (2021): 125. http://dx.doi.org/10.3390/biom11010125.
Full textAbstract:
Background: Breast cancer (BC) is the most common neoplasm in women. Many clinical and preclinical studies investigated the possible relationship between host metabolism and BC. Significant differences among BC subtypes have been reported for glucose metabolism. Insulin can promote tumorigenesis through a direct effect on epithelial tissues or indirectly by affecting the levels of other modulators, such as the insulin-like growth factor (IGF) family of receptors, sex hormones, and adipokines. The potential anti-cancer activity of metformin is based on two principal effects: first, its capacity for lowering circulating insulin levels with indirect endocrine effects that may impact on tumor cell proliferation; second, its direct influence on many pro-cancer signaling pathways that are key drivers of BC aggressiveness. Methods: In the present review, the interaction between BC, host metabolism, and patients’ prognosis has been reviewed across available literature evidence. Conclusions: Obesity, metabolic syndrome, and insulin resistance are all involved in BC growth and could have a relevant impact on prognosis. All these factors act through a pro-inflammatory state, mediated by cytokines originated in fat tissue, and seem to be related to a higher risk of BC development and worse prognosis.
Dissertations / Theses on the topic "Obesity; Neoplasm; Breast Cancer"
1
Johnson, Lisa Godefroy. "The relationship of obesity-related metabolic hormones and prognosis in young women with breast cancer /." Thesis, Connect to this title online; UW restricted, 2003. http://hdl.handle.net/1773/10874.
Full text
2
Gadéa-Deschamps, Émilie. "Impact de la chimiothérapie sur le métabolisme énergétique des patientes atteintes d'un cancer du sein non métastatique : Mécanismes impliqués et conséquences métaboliques." Thesis, Clermont-Ferrand 1, 2014. http://www.theses.fr/2014CLF1MM04.
Full textAbstract:
De nos jours, les femmes sont confrontées à deux tendances épidémiologiques fortes : une constante augmentation de l’incidence de l’obésité, et l’augmentation de l’incidence du cancer du sein. Les Françaises de plus de 50 ans doivent faire face à ces deux problèmes majeurs de santé publique, l’obésité pouvant augmenter le risque de cancer du sein de 30 à 50% en post-ménopause. Néanmoins, grâce aux progrès du dépistage et des thérapies, la mortalité diminue, et le nombre de femmes ayant reçues un traitement contre le cancer du sein augmente. Les traitements par chimiothérapie présentent de nombreux effets secondaires, parmi lesquels une variation de poids significative au cours du traitement (gain ou perte) qui semble perdurer dans le temps. Que ce soit une perte ou un gain de poids, une telle variation a été associée à un mauvais pronostic pour ces patientes. S’agissant de données principalement issues de cohortes américaines présentant un IMC plus élevé qu’une population européenne, le centre Jean Perrin a mené une étude rétrospective afin de vérifier ces résultats sur une population française (Thivat et al. 2010). Cette étude a tout d’abord confirmé qu’un IMC élevé au moment du diagnostic était associé un mauvais pronostic. De plus, la variation de poids observé au cours du traitement par chimiothérapie (gain et perte ≥5% du poids initial) était associée à une augmentation significative du risque de rechute et de décès. Néanmoins, les causes de cette variation de poids et les mécanismes impliqués dans ce mauvais pronostic restent encore mal connus. L’objectif de ce travail est de caractériser la variation de poids en termes de composition corporelle et d’étudier les facteurs de la balance énergétique responsables de ces variations. Les facteurs biologiques associés à la variation de la composition corporelle, potentiellement impliqués dans le mauvais pronostic, sont également étudiés. Le premier chapitre consiste en une étude bibliographique permettant de décrire la pathologie du cancer du sein (partie I), les modifications du métabolisme énergétique suite à un traitement par chimiothérapie (partie II), le rôle du tissu adipeux brun dans la régulation du métabolisme énergétique (partie III) et pour finir, l’impact des modifications du métabolisme énergétique sur la santé des patientes (partie IV). Dans le deuxième chapitre sont présentés les résultats des études réalisées. La première étude, toujours en cours, est exposée sous forme de rapport, tandis que les deux suivantes sont sous forme d’article. Une discussion générale de l’ensemble des résultats dégage les perspectives de recherche à envisager pour donner suite à ce travail<br>Today, women face two strong epidemiological trends: a steady increase in the incidence of obesity, and an increase in the incidence of breast cancer. French women over the age of 50 face these two major public health problems, with postmenopausal obesity increasing the risk of breast cancer by 30 to 50%. Nevertheless, thanks to advances in screening and therapies, mortality is decreasing, and the number of women who have received treatment for breast cancer is increasing.Chemotherapy treatments have many side effects, including a significant change in weight during treatment (gain or loss) that seems to persist over time. Whether it is gain or loss, such weight variation has been associated with poor prognosis for these patients. Since data come mainly from American cohorts with a higher BMI than a European population, the Jean Perrin Center conducted a retrospective study to verify these results in a French population (Thivat et al., 2010). This study first confirmed that a high BMI at the time of diagnosis was associated with a poor prognosis. In addition, the weight change observed during chemotherapy treatment (gain and loss ≥5% of initial weight) was associated with a significant increase in the risk of relapse and death. Nevertheless, the causes of this weight variation and the mechanisms involved in this poor prognosis are still insufficiently understood. The objective of this work is to characterize the variation of weight in terms of body composition and to study the factors of the energy balance responsible for these variations. Biological factors associated with the change in body composition, potentially implicated in the poor prognosis, are also studied. The first chapter consists in a bibliographic review describing the pathology of breast cancer (Part I), the changes in energy metabolism following chemotherapy treatment (Part II), the role of brown adipose tissue in the regulation of energy metabolism (Part III) and finally, the impact of changes in energy metabolism on patient health (Part IV). In the second chapter the results of the studies carried out are presented. The first study, still in progress, is presented as a report, while the next two are in article form. A general discussion of all the results identifies the research perspectives to be considered in order to follow up on this work
3
Zorlini, Renata. "Perfil nutricional pre-operatorio de mulheres com cancer ginecologico e mamario." [s.n.], 2007. http://repositorio.unicamp.br/jspui/handle/REPOSIP/311114.
Full textAbstract:
Orientador: Maria Salete Costa Gurgel<br>Dissertação (mestrado) - Universidade Estadual de Campinas, Faculdade de Ciencias Medicas<br>Made available in DSpace on 2018-09-11T21:11:07Z (GMT). No. of bitstreams: 1
Zorlini_Renata_M.pdf: 756123 bytes, checksum: b912b10737e099427e96e5d68482c9eb (MD5)
Previous issue date: 2007<br>Resumo: Introdução: As mulheres com câncer ginecológico ou de mama apresentam, freqüentemente, alterações do estado nutricional como a desnutrição e a obesidade, devido à própria doença como também ao tratamento a que são submetidas: cirurgia, quimioterapia e/ou radioterapia. Tais alterações podem trazer complicações no pós-operatório como aumento do período de hospitalização, dos custos hospitalares e piora do prognóstico. Para identificar este problema, a avaliação nutricional pode ser o melhor método para tratar os distúrbios nutricionais, como a desnutrição e/ou a obesidade, melhorar a resposta terapêutica e o prognóstico das pacientes. Objetivo: Identificar o perfil nutricional pré-operatório de mulheres com câncer ginecológico ou mamário e correlacioná-lo à localização e estádio da doença e tratamentos oncológicos (quimioterapia e/ou radioterapia) prévios. Sujeitos e Métodos: Trata-se de um estudo de corte transversal com 250 mulheres avaliadas no pré-operatório de cirurgias oncologicas no CAISM/Unicamp, pelo Índice de Massa Corpórea e pela Avaliação Nutricional Subjetiva Global, no período de agosto de 2003 a abril de 2005. Para análise dos dados foram aplicados os testes Qui-Quadrado e Índice de Concordância entre os dois métodos, assumindo-se o nível de significância de 5%. Resultados: O câncer da mama foi o mais freqüente, predominando em 56,2%. A mediana da idade foi de 52 anos; em cerca de 57% dos casos a neoplasia se restringia aos estádios clínicos 0, I e II, e 77% das mulheres não realizaram outro tratamento oncológico pré-cirurgico. A Avaliação Nutricional Subjetiva Global detectou 76% de mulheres eutróficas e 24% desnutridas, enquanto o Índice de Massa Corpórea identificou 34% de mulheres eutróficas, 3,6% desnutridas e 62,4% com sobrepeso/obesidade. A concordância do diagnóstico de eutrofia e desnutrição pelos dois métodos foi baixa [63,8%; kappa (IC 95%) = 0,0884 (-0,07 ¿ 0,24)]. Não foram observadas correlações entre as avaliações nutricionais e os tratamentos prévios e estádios da doença. Quanto à localização anatômica, segundo a Avaliação Nutricional Subjetiva Global, as mulheres com câncer do corpo do útero eram mais desnutridas que as demais (p=0,02). Conclusões: Os achados sugerem que uma avaliação mais criteriosa deva ser empregada para identificação do estado nutricional pré-operatório em mulheres com câncer ginecológico ou mamário. Palavras-chave: perfil nutricional; avaliação nutricional; desnutrição; obesidade; câncer ginecológico; câncer de mama; pré-operatório<br>Abstract: Introduction: The oncologic patient often undergoes several surgical procedures and nutritional status is usually altered during hospitalization, resulting in a worse prognosis. The association between cancer and malnutrition or obesity has many consequences, including increased risk of infection, increased length of hospitalization, poor wound healing, reduction in muscle function and its consequences, thus affecting response to therapy. Objective: To identify the preoperative nutritional profile of women with gynecologic or breast cancer, in correlation with disease site and staging as well as previous treatments. Subjects and Methods: A cross-sectional study of 250 women evaluated by Body Mass Index and Subjective Global Assessment from August 2003 to April 2005. For data analysis, the chi-square test was applied and the agreement between the diagnoses of normal nutrition and malnutrition was calculated by both methods using kappa coefficient and its 95% confidence interval. Results: Breast cancer was the most frequent cancer, predominating in 56.2%. The median age of the patients was 52 years. In about 57% of these women, the tumor was restricted to clinical stages 0, I and II and 77% of the women had not undergone any other oncologic treatment prior to surgery. Subjective Global Assessment detected 76% of nourished women and 24% undernourished women, while Body Mass Index identified 34% of nourished women, 3.6% undernourished women and 62.4% overweight/obese women. A low level of diagnostic agreement between normal nutrition and malnutrition by both methods was observed (63.8%; kappa (95% CI) = 0.0884 (-0.07 ¿ 0.24). No correlation between nutritional evaluation and previous treatment and disease staging was observed. Concerning anatomic site, it was subjectively observed that women with cancer of the uterine corpus were more malnourished than the rest (p=0.02). Conclusions: The findings suggest that a more careful evaluation should be employed to identify preoperative nutritional status in women with gynecologic or breast cancer. Keywords: nutritional profile; assessment; malnutrition; obesity; gynecologic cancer; breast cancer; preoperative<br>Mestrado<br>Ciencias Biomedicas<br>Mestre em Tocoginecologia
4
Gimenez, Rodrigo Pinto 1966. "Expressão proteica da adiponectina, receptores de adiponectina tipos 1 e 2 e da adipocyte fatty acid binding protein no carcinoma invasor, nas suas lesões precursoras e nas lesões benignas da mama = Protein expression of adiponectin, adiponectin receptors types 1 and 2 and adipocyte fatty acid binding protein in breast cancer, its precursor lesions and benign breast lesions." [s.n.], 2013. http://repositorio.unicamp.br/jspui/handle/REPOSIP/311116.
Full textAbstract:
Orientadores: Maria Salete Costa Gurgel, Sílvia de Barros-Mazon<br>Tese (doutorado) - Universidade Estadual de Campinas, Faculdade de Ciências Médicas<br>Made available in DSpace on 2018-08-22T03:12:53Z (GMT). No. of bitstreams: 1
Gimenez_RodrigoPinto_D.pdf: 2727620 bytes, checksum: 505f7780aca2f535e4882eb250f83b9d (MD5)
Previous issue date: 2013<br>Resumo: Introdução: A obesidade tem se mostrado responsável pelo aumento de 30% a 50% dos casos novos de câncer de mama, em particular na pós-menopausa. A mais recente hipótese para explicar tal fato situa os adipócitos e suas funções autócrina, parácrina e endócrina no centro do cenário, através da relação das adipocinas, por ele secretadas, com a obesidade e o câncer de mama. Objetivo: Artigo 1- Comparar o padrão de expressão imunoistoquímica da adiponectina (APN) e dos seus receptores tipos 1 e 2 (adipoR1/R2) no carcinoma invasor (CDI), carcinoma ductal in situ (CDIS) e lesões benignas da mama (BE) e correlacioná-los com parâmetros clínicos e histológicos. Artigo 2- Avaliar a expressão protéica da FABP4 nos tecidos epiteliais e adiposos mamário de portadoras de CDI, CDIS e lesões benignas da mama. Material e Métodos: Foram incluídos os blocos de parafina de 223 mulheres sendo 69 com CDI, 73 com CDIS e 81 com biópsias negativas para câncer de mama, tratadas no CAISM/UNICAMP de janeiro de 2008 a dezembro de 2011, e preparadas lâminas de Tissue Microarray (TMA). A expressão de APN e Adipo R1/R2 foi avaliada no tecido tumoral nos casos CDI e CDIS e no tecido epitelial e nos casos benignos. A expressão de FABP4 foi avaliada no tecido tumoral, na gordura peritumoral (GP) e na gordura mamária distante (GD) nos casos de CDI e CDIS, e no tecido epitelial e gorduras mamários nos casos benignos. Para avaliar uma possível relação entre a expressão dos marcadores entre si e com parâmetros antropométricos, clínicos e histopatológicos, foram utilizados os testes qui-quadrado ou exato de Fisher, Mann-Whitney, Kruskal-Wallis e correlação de Spearman. As determinações foram calculadas considerando o valor de ?=0,05 (p<0,05). Resultados: Artigo 1 - A APN mostrou-se expressa em 65% dos CDI, 48% dos CDIS e 12% das BE e AdipoR1 em 98%, 94% e 71%, respectivamente. Todos os casos de CDI e CDIS expressaram AdipoR2 contra 81% de BE. Nos CDI e CDIS observou-se associação entre maior expressão de APN e tumores RE negativo. No CDIS esta associação foi também observada com RP negativo. Artigo 2 - Observou-se expressão protéica da FABP4 no tecido epitelial em 90% dos CDI, 40% dos CDIS e 28% em BE. Considerando-se a GP e GD esta expressão foi maior nas BE que nos CDI, diferenças consideradas significativas. Nas pacientes com CDI a expressão da FABP4 foi maior quando o diagnóstico ocorreu até 50 anos de idade. A totalidade dos casos expressou moderada a intensamente este marcador no tecido gorduroso periepitelial e distante. Conclusões: As diferenças de expressões protéicas da adiponectina e dos seus receptores AdipoR1/R2 observadas em diferentes diagnósticos mamários sugerem sua participação no complexo mecanismo etiológico destas diferentes condições. Os resultados deste estudo indicam, ainda, que existe uma correlação direta entre expressão protéica da FABP4, câncer de mama e obesidade<br>Abstract: Introduction: Obesity has been shown to be responsible for a 30 to 50% increase in new breast cancer cases, in particular in the postmenopausal period. The most recent hypothesis that explains this fact places adipocytes and its autocrine, paracrine and endocrine functions at center stage, linking adipokines secreted by adipocytes to obesity and breast cancer. Objective: Article 1- to compare immunohistochemistry expression pattern of adiponectin (APN) and its receptors types 1 and 2 (adipoR1/R2) in invasive carcinoma (IDC), ductal carcinoma in situ (CDIS) and benign breast lesions (BE), correlated with clinical and histological parameters. Article 2- To assess FABP4 protein expression in epithelial and adipose breast tissue in women diagnosed with IDC, DCIS and benign breast lesions. Material and Methods: Paraffin-embedded blocks from 223 women were included. Of the total number of women, 69 had IDC CDI, 73 had CDIS and 81 had biopsies negative for breast cancer. The patients have been treated at CAISM/Unicamp from January 2008 to December 2011 and Tissue Microarray (TMA) slides were constructed. Expression of APN and Adipo R1/R2 was assessed in tumor tissue in cases of IDC and DCIS and in epithelial tissue in benign cases. FABP4 expression was evaluated in tumor tissue, peritumoral fat tissue (PF) and distant fat breast tissue (DF) in cases of IDC and DCIS and in the epithelial tissue and breast fat tissue in benign cases. To assess a possible relationship between marker expression and anthropometric, clinical and histopathological parameters, the chi-square test or Fisher's exact test, Mann-Whitney test, Kruskal-Wallis test and Spearman's correlation were used. Determinations were calculated, considering a value ?=0.05 (p<0.05) as significant. Results: Article 1 - APN was shown to be expressed in 65% of IDC, 48% of DCIS and 12% of BE and AdipoR1 in 98%, 94% and 71%, respectively. All IDC and DCIS cases expressed AdipoR2 versus 81% of BE. In IDC and DCIS, an association between a higher level of APN expression and ER-negative tumors was observed. In DCIS, this association was also observed with PR-negative tumors. Article 2 - FABP4 protein expression was observed in epithelial tissue in 90% of CDI, 40% of DCIS and 28% of BE. Considering PF and DF, FABP4 expression had a higher level in BE than in IDC, a difference that was considered significant. In patients with IDC, FABP4 expression was higher when diagnosis was made in patients aged up to 50 years. In all cases, this marker was moderately to intensely expressed in the peri-epithelial and distant fat tissue. Conclusions: Discrepancies in protein expression of adiponectin and its receptors AdipoR1/R2 observed in different breast diagnoses suggest its participation in the complex etiologic mechanism of these different conditions. Our results indicate that there is a direct correlation between FABP4 protein expression, breast cancer and obesity<br>Doutorado<br>Oncologia Ginecológica e Mamária<br>Doutor em Ciências da Saúde
5
Fredriksson, Irma. "Local recurrence after breast conserving surgery in breast cancer /." Stockholm, 2002. http://diss.kib.ki.se/2002/91-7349-255-8/.
Full text
6
Marchena, Carmen L., Stephany I. Urcia, and Carlos Canelo-Aybar. "Prostate cancer detection: the effect of obesity on Asian men." Elsevier B.V, 2015. http://hdl.handle.net/10757/609851.
Full text
7
Saarela, A. (Arto). "Diagnosis and surgical treatment of suspicious nonpalpable breast lesions and early breast cancer." Doctoral thesis, University of Oulu, 1999. http://urn.fi/urn:isbn:9514253604.
Full textAbstract:
Abstract
The purposes of the present research were to evaluate (1)
the value of ultrasonographically guided fine-needle aspiration
biopsy (US-FNAB) in nonpalpable suspicious breast lesions, (2)
the preoperative use of methylene blue staining in nonpalpable
galactographically suspicious breast lesions, (3) the determinants
of positive histologic margins and residual cancer in wire-guided
biopsy (WGB) of nonpalpable breast cancer and in lumpectomy for
early breast cancer and the determinants of positive radiologic
margins and the correlation between radiologic and histologic margins
and residual disease in WGB of nonpalpable breast cancer, (4) the
assessment of lumpectomy margins by touch preparation cytology
in early breast cancer, and (5) the cosmetic outcome of WGB performed
for benign breast lesions.
The sensitivity and specificity of US-FNAB in 90 nonpalpable
breast lesions were 84% and 93%, respectively.
Preoperative methylene blue staining was successful in 22 out of
30 (73%) cases, making subsequent selective minimal volume
microdochectomy easy to perform. Multivariate analysis of 21 prospectively
evaluated variables was done after 71 WGBs of nonpalpable breast
cancer followed by 54 re-excisions. Large mammographic lesions
had more often positive radiologic margins. Multifocality, large
pathologic size and superficial excision were related to positive histologic
margins and multifocality to residual disease in re-excisions.
The sensitivity and specificity of specimen radiography for predicting
histologic margins were 38% and 81% and those
for residual disease 27% and 79%, respectively.
The corresponding figures for histologic margins in predicting
residual disease were 85% and 59%, respectively.
In a prospective series of 55 consecutive lumpectomies for early
breast cancer, positive histologic margins were found more often in
the presence of intraductal cancer and if the pathologic size of
the index tumor was large. Residual disease was found in 38% of
the cases with positive and in 15% of the cases with negative
histologic margins. A multifocal and nonpalpable index tumor predicted
residual cancer in 34 re-excision specimens. The sensitivity and
specificity of touch preparation cytology in predicting histologic margins
were 38% and 85%, respectively. In WGB, the overall
cosmesis 6 months after surgery was satisfactory in 75 % of
the 101 prospectively evaluated patients with benign proven lesions. Cosmesis
was poorer after deep excisions and complications.
The results indicate that US-FNAB is a useful tool in evaluating
nonpalpable suspicious breast lesions. Preoperative methylene blue
staining crucially facilitates selective minimal volume microdochectomy
in three-quarters of cases. To obtain free margins in WGB, mammographically
and pathologically large lesions should be removed with wider excisions
extending down to the fascia. However, radiologic margins in WGB
and histologic margins both in WGB and in lumpectomy for early
breast cancer may be misleading. Re-excision of the biopsy site
of multifocal tumors after WGB and lumpectomy should be considered.
This is also important after superficial excision in WGB due to
the considerable risk of residual disease. Touch preparation cytology
cannot be recommended for the assessment of margins in lumpectomy
specimens of early breast cancer. Cosmetic outcome after WGB of
benign breast lesions is satisfactory in 75 % of cases.
Deep excisions and complications endanger the cosmetic outcome.
Preoperative biopsy and tumor localization methods have proven
their utility; nevertheless, free margins are still difficult to
obtain and to evaluate accurately. The surgeon may often be forced
to choose between free margins and an acceptable cosmetic outcome.
8
Campbell, Bridie. "Beyond Breast Cancer: An exploration of the experiences of middle-aged female breast cancer survivors in Australia." Thesis, Occupational Therapy, 2018. http://hdl.handle.net/2123/17795.
Full textAbstract:
Objective: Middle-aged women (40 – 65 years) who live with, through and beyond breast cancer (survivors), are a relatively under-researched population group, particularly within an Australian context. The unmet needs reported within this population include fatigue, psychological distress, body image concerns, early onset menopause, and a lack of information of these issues. The present study aims to explore how the experiences of breast cancer survivorship impact the lives of Australian middle-aged women (n = 644), and to inform future provision of care and support. Methods: This qualitative study used secondary survey data from the Australian Longitudinal Study of Women’s Health (ALSWH) middle-age cohort gathered between 1996 – 2013. Researchers conducted a thematic analysis using consensus coding on data collected from participants in this group who reported breast cancer (including metastasised) in any survey. Results: This cohort reported a unique experience of breast cancer survivorship due to their age. Analysis developed the following themes: the middle-aged context of breast cancer; care and support, body changes, overcoming fears and maintaining balance; and finding a ‘new normal’. Conclusions: Breast cancer survivorship is a subjective experience; for many it involves chronic limitations and challenges. Investigation and application of survivorship care plans in Australia would benefit from greater inclusion of multidisciplinary professionals. This will help satisfy heretofore unmet information needs and associated psychological distress of breast cancer survivors which go above their biomedical concerns. Further recommendations include development of online support groups providing access to rehabilitation professionals, especially for otherwise isolated rural women.<br>Australian Longitudinal Study of Women's Health
9
Dobson, Jason R. "Nuclear Organization in Breast Cancer: A Dissertation." eScholarship@UMMS, 2013. https://escholarship.umassmed.edu/gsbs_diss/650.
Full textAbstract:
The nuclear matrix (NM) is a fibrogranular network of ribonucleoproteins upon which transcriptional complexes and regulatory genomic sequences are organized. A hallmark of cancer is the disorganization of nuclear architecture; however, the extent to which the NM is involved in malignancy is not well studied.
The RUNX1 and RUNX2 proteins form complexes within the NM to promote hematopoiesis and osteoblastogenesis, respectively at the transcriptional level. RUNX1 and RUNX2 are both expressed in breast cancer cells (BrCCs); however, their genome-wide BrCC functions are unknown. RUNX1 and RUNX2 activate many tumor suppressor pathways in blood and bone lineages, respectively, including attenuation of protein synthesis and cell growth via suppression of ribosomal RNA (rRNA) transcription, which appears contrary to Runx-expression in highly proliferative BrCCs. To define roles for RUNX1 and RUNX2 in BrCC phenotype, we examined the involvement of RUNX1 and RUNX2 in rRNA transcription and generated a genome-wide model for RUNX1 and RUNX2-binding and transcriptional regulation. To validate gene expression patterns identified in our screen, we developed a Real-Time qPCR primer design program, which allows rapid, high-throughput design of primer pairs (FoxPrimer). In BrCCs, RUNX1 and RUNX2 regulate genes that promote invasiveness and do not affect rRNA transcription, protein synthesis, or cell growth. We have characterized in vitro functions of Runx proteins in BrCCs; however, the relationships between Runx expression and diagnostic/prognostic markers of breast cancer (BrCa) in patients are not well studied. Immunohistochemical detection of RUNX1 and RUNX2 in BrCa tissue microarrays reveals RUNX1 expression is associated with early, smaller tumors that are ER+ (estrogen receptor), HER2+, p53-, and correlated with androgen receptor (AR) expression; RUNX2 expression is associated with late-stage, larger tumors that are HER2+. These results show that the functions and expression patterns of NM-associated RUNX1 and RUNX2 are context-sensitive, which suggests potential disease-specific roles.
Two functionally disparate genomic sequence types bind to the NM: matrix associated regions (MARs) are functionally associated with transcriptional repression and scaffold associated regions (SARs) are functionally associated with actively expressed genes. It is unknown whether malignant nuclear disorganization affects the functions of MARs/SARs in BrCC. We have refined a method to isolate nuclear matrix associated DNA (NM-DNA) from a structurally preserved NM and applied this protocol to normal mammary epithelial cells and BrCCs. To define transcriptional functions for NM-DNA, we developed a computational algorithm (PeaksToGenes), which statistically tests the associations of experimentally-defined NM-DNA regions and ChIP-seq-defined positional enrichment of several histone marks with transcriptome-wide gene expression data. In normal mammary epithelial cells, NM-DNA is enriched in both MARs and SARs, and the positional enrichment patterns of MARs and SARs are strongly associated with gene expression patterns, suggesting functional roles. In contrast, the BrCCs are significantly enriched in the silencing mark H3K27me3, and the NM-DNA is enriched in MARs and depleted of SARs. The MARs/SARs in the BrCCs are only weakly associated with gene expression patterns, suggesting that loss of normal DNA-matrix associations accompanies the disease state. Our results show that structural preservation of the in situ NM allows isolation of both MARs and SARs, and further demonstrate that in a disorganized, cancerous nucleus, normal transcriptional functions of NM-DNA are disrupted.
Our studies on nuclear organization in BrCC, show that the disorganized phenotype of the cancer cell nucleus is accompanied by deregulated transcriptional functions of two constituents of the NM. These results reinforce the role of the NM as an important structure-function component of gene expression regulation.
10
Dobson, Jason R. "Nuclear Organization in Breast Cancer: A Dissertation." eScholarship@UMMS, 2004. http://escholarship.umassmed.edu/gsbs_diss/650.
Full textAbstract:
The nuclear matrix (NM) is a fibrogranular network of ribonucleoproteins upon which transcriptional complexes and regulatory genomic sequences are organized. A hallmark of cancer is the disorganization of nuclear architecture; however, the extent to which the NM is involved in malignancy is not well studied.
The RUNX1 and RUNX2 proteins form complexes within the NM to promote hematopoiesis and osteoblastogenesis, respectively at the transcriptional level. RUNX1 and RUNX2 are both expressed in breast cancer cells (BrCCs); however, their genome-wide BrCC functions are unknown. RUNX1 and RUNX2 activate many tumor suppressor pathways in blood and bone lineages, respectively, including attenuation of protein synthesis and cell growth via suppression of ribosomal RNA (rRNA) transcription, which appears contrary to Runx-expression in highly proliferative BrCCs. To define roles for RUNX1 and RUNX2 in BrCC phenotype, we examined the involvement of RUNX1 and RUNX2 in rRNA transcription and generated a genome-wide model for RUNX1 and RUNX2-binding and transcriptional regulation. To validate gene expression patterns identified in our screen, we developed a Real-Time qPCR primer design program, which allows rapid, high-throughput design of primer pairs (FoxPrimer). In BrCCs, RUNX1 and RUNX2 regulate genes that promote invasiveness and do not affect rRNA transcription, protein synthesis, or cell growth. We have characterized in vitro functions of Runx proteins in BrCCs; however, the relationships between Runx expression and diagnostic/prognostic markers of breast cancer (BrCa) in patients are not well studied. Immunohistochemical detection of RUNX1 and RUNX2 in BrCa tissue microarrays reveals RUNX1 expression is associated with early, smaller tumors that are ER+ (estrogen receptor), HER2+, p53-, and correlated with androgen receptor (AR) expression; RUNX2 expression is associated with late-stage, larger tumors that are HER2+. These results show that the functions and expression patterns of NM-associated RUNX1 and RUNX2 are context-sensitive, which suggests potential disease-specific roles.
Two functionally disparate genomic sequence types bind to the NM: matrix associated regions (MARs) are functionally associated with transcriptional repression and scaffold associated regions (SARs) are functionally associated with actively expressed genes. It is unknown whether malignant nuclear disorganization affects the functions of MARs/SARs in BrCC. We have refined a method to isolate nuclear matrix associated DNA (NM-DNA) from a structurally preserved NM and applied this protocol to normal mammary epithelial cells and BrCCs. To define transcriptional functions for NM-DNA, we developed a computational algorithm (PeaksToGenes), which statistically tests the associations of experimentally-defined NM-DNA regions and ChIP-seq-defined positional enrichment of several histone marks with transcriptome-wide gene expression data. In normal mammary epithelial cells, NM-DNA is enriched in both MARs and SARs, and the positional enrichment patterns of MARs and SARs are strongly associated with gene expression patterns, suggesting functional roles. In contrast, the BrCCs are significantly enriched in the silencing mark H3K27me3, and the NM-DNA is enriched in MARs and depleted of SARs. The MARs/SARs in the BrCCs are only weakly associated with gene expression patterns, suggesting that loss of normal DNA-matrix associations accompanies the disease state. Our results show that structural preservation of the in situ NM allows isolation of both MARs and SARs, and further demonstrate that in a disorganized, cancerous nucleus, normal transcriptional functions of NM-DNA are disrupted.
Our studies on nuclear organization in BrCC, show that the disorganized phenotype of the cancer cell nucleus is accompanied by deregulated transcriptional functions of two constituents of the NM. These results reinforce the role of the NM as an important structure-function component of gene expression regulation.
Books on the topic "Obesity; Neoplasm; Breast Cancer"
1
Fantus, I. George. Insulin resistance and cancer: Epidemiology, cellular and molecular mechanisms, and clinical implications. Springer, 2011.
Find full text
2
Brown, Kristy A., and Evan R. Simpson. Obesity and Breast Cancer. Springer New York, 2014. http://dx.doi.org/10.1007/978-1-4899-8002-1.
Full text
3
Kaufmann, M. Therapeutic management of metastatic breast cancer. Walter de Gruyter & Co, 1989.
Find full text
4
McGahan, Lynda. Surveillance mammography after treatment for primary breast cancer. CCOHTA, 2000.
Find full text
5
Swanton, Charles, and Stephen R. D. Johnston. Handbook of metastatic breast cancer. 2nd ed. Informa Healthcare, 2011.
Find full text
6
Petrén-Mallmin, Marianne. Clinical and experimental imaging of breast cancer metastases in the spine. Munksgaard, 1994.
Find full text
7
1952-, Dickson Robert B., and Lippman Marc E. 1945-, eds. Mammary tumor cell cycle, differentiation, and metastasis: Advances in cellular and molecular biology of breast cancer. Kluwer Academic Publishers, 1996.
Find full text
8
1922-, Dao Thomas L., Brodie Angela, Ip Clement, and Organ Systems Program (National Cancer Institute). Breast Cancer Working Group., eds. Tumor markers and their significance in the management of breast cancer: Proceedings of a workshop held in Bethesda, Maryland, March 6, 1985. Liss, 1986.
Find full text
9
Lawrence, Paszat, and Canadian Coordinating Office for Health Technology Assessment., eds. A population-based cohort study of surveillance mammography after treatment of primary breast cancer. Canadian Coordinating Office for Health Technology Assessment, 2001.
Find full text
10
Julia, Gee, Nicholson Robert I, and SpringerLink (Online service), eds. Therapeutic Resistance to Anti-Hormonal Drugs in Breast Cancer: New Molecular Aspects and their Potential as Targets. Springer Netherlands, 2009.
Find full textBook chapters on the topic "Obesity; Neoplasm; Breast Cancer"
1
Fortner, Renée T., Verena Katzke, Tilman Kühn, and Rudolf Kaaks. "Obesity and Breast Cancer." In Obesity and Cancer. Springer International Publishing, 2016. http://dx.doi.org/10.1007/978-3-319-42542-9_3.
Full text
2
Brown, Kristy A., and Evan R. Simpson. "Estrogens, Adiposity and the Menopause." In Obesity and Breast Cancer. Springer New York, 2013. http://dx.doi.org/10.1007/978-1-4899-8002-1_1.
Full text
3
Brown, Kristy A., and Evan R. Simpson. "The Link Between Obesity and Breast Cancer Risk: Epidemiological Evidence." In Obesity and Breast Cancer. Springer New York, 2013. http://dx.doi.org/10.1007/978-1-4899-8002-1_2.
Full text
4
Brown, Kristy A., and Evan R. Simpson. "Adipose-Derived and Obesity-Related Factors and Breast Cancer." In Obesity and Breast Cancer. Springer New York, 2013. http://dx.doi.org/10.1007/978-1-4899-8002-1_3.
Full text
5
Brown, Kristy A., and Evan R. Simpson. "Estrogen Biosynthesis." In Obesity and Breast Cancer. Springer New York, 2013. http://dx.doi.org/10.1007/978-1-4899-8002-1_4.
Full text
6
Brown, Kristy A., and Evan R. Simpson. "Therapy Aimed at Breaking the Linkage Between Obesity and Breast Cancer." In Obesity and Breast Cancer. Springer New York, 2013. http://dx.doi.org/10.1007/978-1-4899-8002-1_5.
Full text
7
Iyengar, Neil M., Patrick G. Morris, Clifford A. Hudis, and Andrew J. Dannenberg. "Obesity, Inflammation, and Breast Cancer." In Obesity, Inflammation and Cancer. Springer New York, 2013. http://dx.doi.org/10.1007/978-1-4614-6819-6_8.
Full text
8
Radimer, Kathy L., and Christopher Bain. "Risks Associated with Obesity." In Reducing Breast Cancer Risk in Women. Springer Netherlands, 1995. http://dx.doi.org/10.1007/978-94-011-0489-0_16.
Full text
9
Engin, Atilla. "Obesity-associated Breast Cancer: Analysis of risk factors." In Obesity and Lipotoxicity. Springer International Publishing, 2017. http://dx.doi.org/10.1007/978-3-319-48382-5_25.
Full text
10
Nyrop, Kirsten A., Jordan T. Lee, Erin A. O’Hare, Chelsea Osterman, and Hyman B. Muss. "Obesity, Weight Gain, and Weight Management." In Common Issues in Breast Cancer Survivors. Springer International Publishing, 2021. http://dx.doi.org/10.1007/978-3-030-75377-1_13.
Full textConference papers on the topic "Obesity; Neoplasm; Breast Cancer"
1
Rocha, Marina Elias, Jaziane Gonçalves Santos, Éllyda Vanessa Leonel Oliveira, and Geffson Damaceno Machado. "Male breast cancer." In Brazilian Breast Cancer Symposium 2024. Mastology, 2024. http://dx.doi.org/10.29289/259453942024v34s1101.
Full textAbstract:
Objective: This study aimed to describe breast cancer in the male population in the literature. Methodology: An integrative literature review was carried out from 2014 to 2019, using the PubMed, Medline, and Scielo databases. Results: Malignant breast neoplasia is much more common in women and rare in men, accounting for around 1% of diagnoses, making it an uncommon cancer and being more common in patients aged 60–70 years. Lobular and the most common is ductal carcinoma, and the diagnosis is made through clinical ultrasound, mammography, and pathological studies. The assessment of genetic factors in first-degree relatives is very important. They are present in 20% of cases. We have several risk factors: hormonal, such as prostate cancer treatment, and the use of transsexuals. Obesity is one of the most frequent causes, and in cases of environmental issues, for both men and women, the treatment is similar. As initial surgery for the removal of breast tissue, nipple, and axillary emptying, others such as hormone therapy, chemotherapy, and radiotherapy have not been studied much, but due to the positivity in the receptors, it has been chosen in adjuvant treatment and followed the female guidelines. Of 80, 90% of diagnosed patients have positive estrogen and progesterone receptors. Conclusion: Breast cancer is very similar between men and women. Differences in prognostic characteristics may necessitate a different approach compared with female breast cancer.
2
Paiva, Jorge Luiz Firmo de, Ana Carolina Betto Castro, Helena Varago Assis, Fernando Aparecido Pazini, and Marcel Arouca Domeniconi. "MALE BREAST CANCER CASE REPORT OF AN INVASIVE CARCINOMA OF A NONSPECIAL AND INVASIVE DUCTAL TYPE 2 IN A MALE PATIENT." In XXIV Congresso Brasileiro de Mastologia. Mastology, 2022. http://dx.doi.org/10.29289/259453942022v32s1054.
Full textAbstract:
Male breast cancer (MMC) corresponds to 0.5% of cases of malignant neoplasms in men. Among the associated risk factors are black ethnicity, age over 60 years, family history, BRCA1 and BRCA2 gene mutations, Klinefelter syndrome, the use of exogenous estrogen, gynecomastia, obesity, and a history of chest radiation. Regarding diagnosis and treatment, the standard trend for female breast cancer is still followed, with few studies in men. We report the case of an 81-yearold black patient with few risk factors exposed in the literature. On physical examination at entry, he presented an exophytic lesion in the right breast and palpable and hardened lymph nodes in the right axillary region. With an established diagnosis of nonspecial type invasive carcinoma and invasive ductal carcinoma without other specifications by previous biopsy, a modified right radical mastectomy was performed with right axillary dissection and according to the pathological examination with pT4b pN1 pMx staging. Thus, as a result of the good evolution of the condition, the patient was discharged 2 days after the surgery to the oncology clinic, in order to monitor the condition.
3
Belluco, Rosana Zabulon Feijó, Carolina Gaze Gonçalves Fontenele Gomes, Camila Pires Marinho, et al. "Breast neoplasm with distinct histological subtypes: A case report." In Brazilian Breast Cancer Symposium 2023. Mastology, 2023. http://dx.doi.org/10.29289/259453942023v33s1048.
Full textAbstract:
Introduction: Breast cancer is a heterogeneous disease, divided into many subtypes, the most common being invasive ductal. Breast tumors can be derived from epithelial tissue or mesenchymal cells. Most malignant breast tumors are made up of a single type of tumor. Cases where there are two or more types of malignant tumors occurring at the same time are rare. We report a case with different types of malignancies, i.e., non-special invasive ductal carcinoma, metaplastic carcinoma, and squamous cell carcinoma occurred together. Case report: A woman, 56 years old, with no family history of gynecological neoplasia, sought care referring to a painful and erythematous nodule in her left breast for about 25 days. On physical examination, a 15×11 cm, slightly mobile nodule with irregular borders was noticed in the left breast and palpable axillary lymph nodes. The mammogram showed an isodense nodule with internal calcifications, measuring 10.2×9.4×7.2 cm, in the superolateral quadrant (QSL) of the left breast (ME) — BI-RADS V. The central biopsy showed nonspecial invasive breast carcinoma (NOS), triple-negative, and KI67 30%. She underwent neoadjuvant chemotherapy, and 5 months after the start, she showed evidence of tumor progression. The tumor was ulcerated and occupying the entire QSL of ME and on palpation of the armpit, multiple hardened lymph nodes on the left. Left radical mastectomy with axillary lymphadenectomy was performed. The anatomopathological examination of the specific specimen revealed different tumor types: ulcerated and moderately differentiated squamous cell carcinoma, invasive metaplastic breast carcinoma, with a negative immunohistochemical profile for RP, ER, and HER2, positive cytokeratin 7, and 70% Ki67. Two months after the mastectomy, she had tumor recurrence and underwent a new surgical approach. Plastron histopathology showed squamous cell carcinoma infiltrating skin, negative estrogen and progesterone receptors, and positive p63. She underwent radiotherapy and is currently being followed up, with no signs of recurrence.
4
Alves, Katyane Larissa, Frank Lane Braga Rodrigues, Sebastião Alves Pinto, and Ruffo de Freitas-Junior. "SPOROTRICHOSIS IN AXILLARY LYMPHADENOPATHY SIMULATING RECURRENCE OF BREAST NEOPLASM: A CASE REPORT." In Brazilian Breast Cancer Symposium 2022. Mastology, 2022. http://dx.doi.org/10.29289/259453942022v32s2085.
Full textAbstract:
Introduction: Sporotrichosis is a mycosis caused by dimorphic fungi of the Sporothrix complex. It is an anthropozoonotic disease that can be transmitted to humans by contact with plants or animals, especially infected cats. Clinical presentation may vary depending on the host’s immunological condition. The diagnosis of sporotrichosis requires material obtained from lesion biopsies, which can be submitted for culture and microscopy. Case report: A 57-year-old female patient, being followed up for carcinoma in situ of the left breast, presented with ipsilateral axillary lymphadenopathy on routine examinations. She underwent ultrasound-guided core-needle biopsy of a suspicious lymph node in the left axilla, with a diagnosis of chronic granulomatous lymphadenitis containing fungal yeasts, suggestive of sporotrichosis. Treatment with systemic antifungal itraconazole was started with a good response. Discussion: Sporotrichosis is an important differential diagnosis for lymphadenopathy, associated or not with neoplasms being treated in our country. In the presented case, the patient had an oligosymptomatic presentation of sporotrichosis, probably a subacute form of the cutaneous-lymphatic presentation, initially evidenced only on evaluation with imaging methods, with a good response to systemic antifungal therapy with itraconazole, also remaining without signs of recurrence of breast cancer. Conclusion: Considering Brazil as an endemic area for sporotrichosis, the description of cases such as this one allows us to discuss and remember this differential diagnosis in clinical situations and/or in imaging examinations, even in patients undergoing follow-up for malignant neoplasms.
5
Lima, Fernanda Teresa de, Madeleyne Beatriz Boado Quiroga Cardenas, Gabriela de Almeida Vasconcelos Costa, et al. "MALE BREAST CANCER ASSOCIATED WITH A LARGE DELETION IN BLM GENE – REPORT OF A CASE." In Brazilian Breast Cancer Symposium 2022. Mastology, 2022. http://dx.doi.org/10.29289/259453942022v32s2077.
Full textAbstract:
Malignant breast neoplasm in men is rare, corresponding to less than 1% of all breast neoplasms, and 100 times less frequent than in women. It is molecularly different from female breast cancer, and germline pathogenic mutations in genes aside from BRCAs have been recently associated with an increased risk of male breast cancer. Here, we report an elderly male, 71 years old, with a malignant neoplasm in the left breast, with positive hormone receptors, HER2-negative, and Ki-67 of 25%. A modified radical mastectomy was performed, and the surgical specimen showed a micropapillary invasive mammary carcinoma, 1.9 cm, 2 of 11 lymph nodes positive, pT1cpN1acM0. He was treated with adjuvant chemotherapy and radiotherapy, followed by endocrine therapy. His mother had breast cancer at 50 years, and his smoking father died of lung cancer. During his treatment, a multigene panel was done and a heterozygous likely pathogenic large deletion involving exons 20–22 of the BLM gene was found, associated with a variant of unknown significance in the same gene; c.3427G>A; p.(Glu1143Lys). All his three daughters harbor the same mutation. The risk of breast cancer in association with a heterozygous pathogenic variant in the BLM gene is still controversial because of its ability to cause tumors when not associated with polymorphisms in other homologous recombination genes, which poses a challenge for genetic counseling, surveillance, and management. This report aims to add data and clinical evidence to the attempts to elucidate the role of BLM germline variants in breast cancer predisposition.
6
Dannenberg, Andrew J. "Abstract PL05-02: Obesity, inflammation and breast cancer." In Abstracts: Twelfth Annual AACR International Conference on Frontiers in Cancer Prevention Research; Oct 27-30, 2013; National Harbor, MD. American Association for Cancer Research, 2013. http://dx.doi.org/10.1158/1940-6215.prev-13-pl05-02.
Full text
7
Dannenberg, Andrew J. "Abstract CN07-02: Obesity, inflammation, and breast cancer." In Abstracts: Thirteenth Annual AACR International Conference on Frontiers in Cancer Prevention Research; September 27 - October 1, 2014; New Orleans, LA. American Association for Cancer Research, 2015. http://dx.doi.org/10.1158/1940-6215.prev-14-cn07-02.
Full text
8
Griggs, J., E. Gillespie, D. Hanauer, C. Jagielski, M. Sabel, and M. Sorbero. "Obesity and Angiolymphatic Invasion in Primary Breast Cancer." In Abstracts: Thirty-Second Annual CTRC‐AACR San Antonio Breast Cancer Symposium‐‐ Dec 10‐13, 2009; San Antonio, TX. American Association for Cancer Research, 2009. http://dx.doi.org/10.1158/0008-5472.sabcs-09-5151.
Full text
9
Dannenberg, Andrew J. "Abstract SY12-03: Obesity, inflammation and breast cancer." In Proceedings: AACR 106th Annual Meeting 2015; April 18-22, 2015; Philadelphia, PA. American Association for Cancer Research, 2015. http://dx.doi.org/10.1158/1538-7445.am2015-sy12-03.
Full text
10
Batista, Maria Stefania Nóbrega, and Lara Moreira Mendes Carneiro. "Association between obesity and breast cancer in premenopause." In II INTERNATIONAL SEVEN MULTIDISCIPLINARY CONGRESS. Seven Congress, 2023. http://dx.doi.org/10.56238/homeinternationalanais-025.
Full textAbstract:
Abstract In Brazil, excluding non-melanoma skin tumors, breast cancer is the most common in women. The number of cancer deaths also increased, from 6.2 million in 2000 to 10 million in 2020. More than one in six deaths is due to cancer (WHO, 2021). In addition to well-established risk factors such as female gender, age, positive family history, genetic mutations, proliferative breast changes, high breast density breasts, early menarche, late menopause and radiation exposure, some researchers associate body constitution with the risk of breast cancer development. As obesity and cancer are diseases that affect millions of people and have important consequences it is necessary to identify the relationship between these two events.
Reports on the topic "Obesity; Neoplasm; Breast Cancer"
1
Clarke, Robert R. Obesity and Breast Cancer. Defense Technical Information Center, 2005. http://dx.doi.org/10.21236/ada442187.
Full text
2
Surmacz, Eva. Obesity and Postmenopausal Breast Cancer: Leptin-Estrogen Cross-Talk. Defense Technical Information Center, 2004. http://dx.doi.org/10.21236/ada429997.
Full text
3
Samavat, Hamed. Green Tea Modulation of Obesity and Breast Cancer Risk. Defense Technical Information Center, 2013. http://dx.doi.org/10.21236/ada581017.
Full text
4
Avni, Dorit. Targeting Sphingosine-1-Phosphate Axis in Obesity-Promoted Breast Cancer. Defense Technical Information Center, 2016. http://dx.doi.org/10.21236/ada636997.
Full text
5
Lin, Yawei, Yi Chen, Rongrong Liu, and Baohua Cao. Effect of exercise on rehabilitation of breast cancer surgery patients: A systematic review and meta-analysis of randomized controlled trials. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, 2022. http://dx.doi.org/10.37766/inplasy2022.10.0065.
Full textAbstract:
Review question / Objective: Exercise after breast cancer surgery has proved beneficial to rehabilitation. We evaluate the best exercise for different post-surgery complications. Information sources: China National Knowledge Infrastructure, Wanfang Data Knowledge Service Platform, VIP China Science and Technology Journal Database, China Biology Medicine, EMBASE and PubMed databases were searched. Combinations of breast cancer (“breast tumor”,“breast carcinoma”,“mammary carcinoma”,“breast neoplasm”) and rehabilitation exercise (“exercise”,“physical therapy”) were employed when screening abstracts/keywords of articles. Two researchers independently searched, read the title and abstract of the literature, read the full text of the preliminary included literature, and extracted the data. In case of divergence, a third researcher was consulted.
6
Griffith, Thomas S. Effect of Obesity and Chronic Inflammation on TRAIL-Based Immunotherapy for Advanced Breast Cancer. Defense Technical Information Center, 2013. http://dx.doi.org/10.21236/ada584093.
Full text
7
Griffith, Thomas S. Effect of Obesity and Chronic Inflammation on TRAIL-Based Immunotherapy for Advanced Breast Cancer. Defense Technical Information Center, 2014. http://dx.doi.org/10.21236/ada604607.
Full text
8
Samad, Fahumiya. Adipose Estrogen and Increased Breast Cancer Risk in Obesity: Regulation by Leptin and Insulin. Defense Technical Information Center, 2006. http://dx.doi.org/10.21236/ada468503.
Full text
9
Bowers, Laura. Obesity and Postmenopausal Breast Cancer Risk: Determining the Role of Growth Factor-Induced Aromatase Expression. Defense Technical Information Center, 2013. http://dx.doi.org/10.21236/ada585228.
Full text
10
Bowers, Laura. Obesity and Postmenopausal Breast Cancer Risk: Determining the Role of Growth Factor-Induced Aromatase Expression. Defense Technical Information Center, 2014. http://dx.doi.org/10.21236/ada596733.
Full text